Rhumbline Advisers Homology Medicines, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$0.83 - $1.12 $973 - $1,313	1,173 New	1,173 $1,000
Q2 2022 Aug 11, 2022	SELL	$1.39 - $3.12 $78,833 - $176,950	-56,715 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$2.6 - $4.17 $8,907 - $14,286	-3,426 Reduced 5.7%	56,715 $172,000
Q4 2021 Feb 10, 2022	BUY	$3.64 - $7.78 $480 - $1,026	132 Added 0.22%	60,141 $219,000
Q3 2021 Nov 12, 2021	BUY	$6.01 - $8.71 $5,060 - $7,333	842 Added 1.42%	60,009 $472,000
Q2 2021 Aug 05, 2021	BUY	$6.02 - $9.64 $131,693 - $210,884	21,876 Added 58.66%	59,167 $430,000
Q1 2021 May 06, 2021	SELL	$9.17 - $14.8 $31,682 - $51,134	-3,455 Reduced 8.48%	37,291 $351,000
Q4 2020 Feb 10, 2021	BUY	$8.92 - $13.29 $25,314 - $37,717	2,838 Added 7.49%	40,746 $460,000
Q3 2020 Nov 12, 2020	SELL	$9.94 - $16.59 $49,163 - $82,054	-4,946 Reduced 11.54%	37,908 $406,000
Q2 2020 Aug 13, 2020	BUY	$12.07 - $19.34 $166,698 - $267,104	13,811 Added 47.55%	42,854 $651,000
Q1 2020 May 06, 2020	BUY	$12.5 - $22.04 $3,225 - $5,686	258 Added 0.9%	29,043 $451,000
Q4 2019 Feb 05, 2020	BUY	$11.42 - $22.19 $3,254 - $6,324	285 Added 1.0%	28,785 $596,000
Q3 2019 Oct 23, 2019	BUY	$14.74 - $22.28 $17,363 - $26,245	1,178 Added 4.31%	28,500 $516,000
Q2 2019 Aug 14, 2019	BUY	$18.35 - $30.34 $117,880 - $194,904	6,424 Added 30.74%	27,322 $535,000
Q1 2019 May 01, 2019	SELL	$19.76 - $29.57 $7,153 - $10,704	-362 Reduced 1.7%	20,898 $580,000
Q4 2018 Jan 31, 2019	BUY	$18.39 - $26.3 $226,086 - $323,332	12,294 Added 137.12%	21,260 $475,000
Q3 2018 Nov 07, 2018	BUY	$15.54 - $22.86 $139,331 - $204,962	8,966 New	8,966 $205,000

Others Institutions Holding FIXX

# of Institutions

Shares Held

66.2K

Call Options Held

Put Options Held

View Full List

About Homology Medicines, Inc.

Ticker FIXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,402,000
Description
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...

More about FIXX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account